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MicroRNA-150 regulates the cytotoxicity of natural killers
by targeting perforin-1
Nayoung Kim, PhD,a Miju Kim, PhD,c,d Sohyun Yun, PhD,a Junsang Doh, PhD,c,d Philip D. Greenberg, MD,e
Tae-Don Kim, PhD,a,b and Inpyo Choi, PhDa,b Daejeon and Pohang, Korea, and Seattle, WashBackground: Perforin-1 (Prf1) is the predominant cytolytic
protein secreted by natural killer (NK) cells. For a rapid
immune response, resting NK cells contain high Prf1 mRNA
concentrations while exhibiting minimal cytotoxicity caused by
a blockage of Prf1 protein synthesis, implying that an unknown
posttranscriptional regulatory mechanism exists.
Objective: We sought to determine whether microRNA-150
(miR-150) posttranscriptionally regulates Prf1 translation in
both mouse and human NK cells at rest and at various time
points after activation.
Methods: Mouse NK cells with a targeted deletion of miR-150
(miR-1502/2 NK cells), primary human NK cells, and NK92 MI
cells were used to investigate the role of miR-150 in NK cells.
NK cell cytotoxicity assays and Western blotting proved that
activated miR-1502/2 NK cells expressed upregulated Prf1,
augmenting NK cell cytotoxicity. When immunodeficient mice
were injected with miR-1502/2 NK cells, there was a significant
reduction in tumor growth and metastasis of B16F10 melanoma.
Results: We report that miR-150 binds to 39 untranslated
regions of mouse and human Prf1, posttranscriptionally
downregulating its expression. Mouse wild-type NK cells
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Open access under CC BY-NC-ND license.IL-15, which led to corresponding repression and induction of
Prf1 during rest and after IL-15 activation, respectively.
Conclusion: Our results indicate that miR-150 is a common
posttranscriptional regulator for Prf1 in mouse and human NK
cells that represses NK cell lytic activity. Thus the therapeutic
control of miR-150 in NK cells could enhance NK cell–based
immunotherapy against cancer, providing a better clinical
outcome. (J Allergy Clin Immunol 2014;134:195-203.)
Key words: miR-150, NK cells, perforin-1, NK cell cytotoxicity,
post-transcriptional regulation, immunotherapy, tumor growth and
metastasis
Natural killer (NK) cells kill target cells predominantly by
secreting granule toxins, including perforin-1 (Prf1) and gran-
zymes.1-3 Prf1 is a pore-forming protein, and granzymes are
structurally related serine proteases that lyse target cell protein
at specific aspartate residues.4,5 Prf1 disturbs the target cell mem-
brane and facilitates the entry, trafficking, or both of granzymes.6
Unlike multiple granzymes, which can compensate each other,
Prf1 is encoded by a single gene and does not have any functional
redundancy.7
NK cells kill target cells ‘‘naturally’’ without prior antigen-
specific recognition, allowing for rapid induction of lytic
activity.8 For prompt immune responses, resting NK cells are in
a ‘‘prearmed’’ state, containing high concentrations of Prf1
mRNA, but they are minimally cytotoxic because of a blockage
of Prf1 translation.9 On target recognition, activated NK cells
immediately arm themselves with preformed Prf1 mRNA, corre-
lating with an increase in Prf1 protein levels. Therefore Prf1 is
posttranscriptionally regulated by unknown regulators in resting
NK cells.
MicroRNAs (miRNAs) are small noncoding RNAs of
approximately 22 nucleotides that function as posttranscrip-
tional inhibitors complementary to the 39 untranslated region
(UTR) of their target mRNAs.10 Over the past few years,
emerging data have implied that endogenously generated miR-
NAs are posttranscriptional regulators of immune cell develop-
ment and function.11 miR-150 has been identified as a
lymphocyte-specific miRNA because it is predominantly ex-
pressed in the lymph nodes, spleen, and thymus and is highly
upregulated during lymphocyte maturation. miR-150 expression
increases sharply in mature B and T lymphocytes, as well as in
mature NK and invariant NK T cells, although not in their
progenitors.12-16
Although miR-150 expression is upregulated during lympho-
cyte maturation, it is downregulated again during the activation of
mature B and T cells. Xiao et al14 reported that miR-150 expres-
sion was downregulated in activated B cells and that miR-150–
deficient mice exhibit enhanced humoral and T cell–dependent
antibody responses with increased steady-state immunoglobulin
levels. Collectively, miR-150 appears to be inversely associated195
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relationship between miR-150 and the activation of NK cells has
not yet been shown.
In this study we report that miR-150 binds to the 39 UTR of
mouse and human Prf1, posttranscriptionally downregulating its
expression. Mouse wild-type (WT) NK cells exhibited biphasic
upregulated and downregulated miR-150 expression in response
to IL-15, which led to corresponding repression and induction of
Prf1 during rest and after IL-15 activation, respectively. Primary
human NK cells also display downregulated miR-150 and
augmented Prf1 in response to IL-15. Our results suggest that
miR-1502/2 NK cells might provide clinical benefit to minimize
spontaneous activation in resting NK cells while maximizing
cytotoxicity in activated NK cells. Therapeutic modulation of
miR-150 might be a promising new approach for enhancing
NK cell–mediated immunotherapy to treat various human
pathologies.METHODS
For a detailed description of the methods used in this study, see Tables E1
and E2 and the Methods section in this article’s Online Repository at www.
jacionline.org.RESULTS
miR-150 expression is inversely proportional to Prf1
protein expression in both mouse and human NK
cells during IL-15 activation
The expression of miR-150 in mouse WT NK cells exhibited
a biphasic pattern during IL-15 stimulation. The miR-150 level
was sharply increased nearly 2-fold at 4 hours and maintained
for a time. Then its level was markedly decreased to less than
the level of resting NK cells at 24 hours and further down-
regulated at 72 hours. The miR-150 level was negatively
associated with expression of Prf1 protein (Fig 1, A). Primary
human NK cells showed gradually decreased expression of
miR-150 and increased levels of Prf1 protein in response to
IL-15 (Fig 1, B). In both mouse and human NK cells, relatively
high abundance of miR-150 and sustained expression of Prf1
and granzyme B (GzmB) protein were observed during the first
6 hours of IL-15 stimulation. Then Prf1 and GzmB protein
expression started to increase, accompanied by reduced expres-
sion of miR-150 at 24 hours (Fig 1, C and D, top). In addition,
GzmB mRNA expression was notably increased in a time-dependent manner correlating with an increase in GzmB pro-
tein levels, but abundant mRNA of Prf1 in resting NK cells
remained largely unchanged during IL-15 activation in both
mouse and human NK cells (Fig 1, C and D, bottom). This im-
plies that Prf1 could be posttranscriptionally repressed by miR-
150 in NK cells at rest and earlier time points after IL-15
activation.miR-1502/2 NK cells have augmented Prf1 protein
expression and enhanced NK cell cytotoxicity
Resting WT and miR-1502/2 NK cells minimally expressed
Prf1 protein, but Prf1 protein was amplified in miR-1502/2 NK
cells at 48 and 72 hours of IL-15 stimulation. However, Prf1
mRNA abundance did not change over time (Fig 2, A). After 48
hours of IL-15 stimulation, miR-1502/2 NK cells exhibited
enhanced cytotoxicity by approximately 2-fold at an effector/
target (E/T) ratio of 5:1 (Fig 2, B). Collectively, abundant Prf1
mRNAwas posttranscriptionally suppressed in resting NK cells,
but miR-1502/2 NK cells augmented Prf1 protein expression
and cytotoxicity on IL-15 activation.WT and miR-1502/2 NK cells have similar NK cell
receptor profiles, degranulation, and death
receptor/ligand interactions
NK cells express various receptors to recognize target cells.
Therefore we examined a broad range of activating NK cell
receptors (NKG2D, NKp46, and Ly49D), inhibitory receptors
(Ly49C/I, Ly49G2, and Ly49A), IL-15 receptors (CD122 and
CD132), and chemokine receptors (CXCR5 and CCR6). IL-15–
activated WT and miR-1502/2 NK cells displayed similar
frequencies in the receptor repertoire, including IL-15 receptors,
and little or no chemokine receptor expression (Fig 3, A). It led
to similar NK cell degranulation evidenced by the intensity of
CD107a in WT and miR-1502/2 NK cells after treatment with
antibody against NKp46 in the presence or absence of target
cells (Fig 3, B). NK cell cytotoxicity can also be mediated in
the absence of Prf1 through engagement of death receptors
(eg, Fas/CD95) on target cells through their cognate ligands
(eg, Fas ligand) on NK cells.17 We investigated the levels of 2
key effector ligands, Fas ligand and TNF-related apoptosis-
inducing ligand, and the death receptor CD95 in IL-15–acti-
vated NK cells. miR-150 had no profound effects on the
expression of these ligands and receptors (Fig 3, A and C).
These data suggest that the augmented cytotoxicity of miR-
1502/2 NK cells is caused predominantly by enhanced Prf1
and not by significant changes in NK cell receptor profiles,
IL-15 receptor–mediated signaling pathways, or death recep-
tor/ligand interactions.miR-1502/2 NK cells show that potent lytic granules
hit at the immunologic synapse
NK cells are functionally heterogeneous, and thus only a
small portion of NK cells kill target cells.18 Lytic granules of
NK cells were labeled with LysoSensor Green, and target cells
were labeled with DDAO-SE and then cocultured in propidium
iodide (PI)–containing media to assess the dynamics of individ-
ual NK cell cytotoxicity. Larger amounts of lytic granules con-
taining Prf1 and GzmB were found in miR-1502/2 NK cells
FIG 1. miR-150 is involved in the posttranscriptional regulation of Prf1 in NK cells. A and B, miR-150 and
Prf1 protein levels were inversely plotted as means 6 SDs in primary mouse (Fig 1, A) and human (Fig 1, B)
NK cells. C and D, Protein and mRNA levels of Prf1 and GzmB were determined in mouse (Fig 1, C) and
human (Fig 1, D) NK cells during IL-15 stimulation. Results are representative of 3 independent
experiments.
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tensity, showing an approximately 2-fold increase (Fig 4, A).
In accordance, mean fluorescence intensity values of intracyto-
plasmic Prf1 determined by means of flow cytometry showed
an increased Prf1 protein level in miR-1502/2 NK cells (Fig
4, B). Additionally, WT and miR-1502/2 NK cells were stained
with CD107a, which is a sensitive marker of NK cell degranu-
lation,19 in the absence or presence of target cells. WT and
miR-1502/2 NK cells were minimally degranulated without
targets but substantially degranulated after simulation with
target cells. However, miR-150 had no significant effects on
the extent of degranulation, and thus the overall degree of
degranulation was similar in WT and miR-1502/2 NK cells
(Fig 4, C).
To understand NK cell–target cell interactions, we examined
sequential stages of lytic synapses: the initiation, the effector, and
termination stages. In the initiation stage NK cells transiently
contact target cells with either diffused granules (step A) orpolarized granules (step B). In the effector stage NK cells formed
stable contacts with their targets and polarized lytic granules to
distal poles (step C). Then lytic granules were transported to the
immunologic synapse (step D). In the termination stage NK cells
eventually killed target cells, as determined either by the forma-
tion of membrane blebs (step E) or an increase in PI fluorescence
(Fig 4, D, right panel). These sequential steps are shown in Fig 4,
E. Among NK cells encountering target cells, the percentages of
NK cells remaining at each step at the end of 2-hour time-lapse
imaging were measured and plotted in Fig 4, F (see Videos
E1-E5 in this article’s Online Repository at www.jacionline.org
for each case). The kinetics of steps C, D, and E in WT and
miR-1502/2NK cells were further assessed at various time points
after coculture. Throughout the experiments, the higher percent-
age ofWTNK cells remained at step D, but miR-1502/2NK cells
exhibited higher cytotoxicity than WT NK cells when the dura-
tion of NK cell–target cell contact became longer than 60 minutes
(Fig 4,G andH). This suggests that polarized granules inWT NK
FIG 2. miR-1502/2 NK cells exhibit upregulation of Prf1 and enhanced NK cell cytotoxicity. A, Protein and
mRNA levels of Prf1 in WT and miR-1502/2 NK cells after stimulation with IL-15. B, NK cell cytotoxicity
was measured by using standard 4-hour 51Cr-release assays. Data represent means6 SDs of 3 independent
experiments. *P < .05, Student t test.
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cells to kill target cells. Because the levels of degranulation
were comparable between WT and miR-1502/2 NK cells (Fig
4, C), it is likely that miR-1502/2 NK cells exhibit more potent
lytic hits to target cells than WT NK cells, potentially because
of higher content of lytic granules.miR-150 directly targets Prf1 in both mouse and
human NK cells
Aralkylamine N-acetyltransferase (AANAT) reporter assays
were performed to test whether miR-150 directly targets Prf1.20
AANAT reporter plasmids contain a neomycin resistance gene
(NeoR) and AANAT coding region attached to GzmB 39 UTR
or Prf1 39 UTR (Fig 5, A). According to the miRanda algorithm
(www.microrna.org), miR-150 has 1 putative binding site in the
39 UTR of mouse Prf1 (Fig 5, B). Moreover, it has a predicted
binding site in the 39 UTR of both human GzmB and Prf1,
which have less complementary base pairing compared with
mouse Prf1 (Fig 5, B and C). The miR-150 mimic did not
change the expression of AANAT containing the 39 UTR of
mouse or human GzmB, suggesting GzmB was not the real
target of miR-150. In contrast, miR-150 mimic significantly
reduced the expression of AANAT containing mouse Prf1 39
UTR in a dose-dependent manner (Fig 5, D, top) and human
Prf1 39 UTR to a lesser extent, as predicted by less complemen-
tarity (Fig 5, E, top). The miR-150 mutant, which had mutations
in the 59 end of miRNA (referred to as the seed region; Fig 5, B
and C), lost binding capacity to the target and thus attenuated its
inhibitory effects on mouse or human Prf1 39 UTR (Fig 5, D and
E, top). The levels of AANAT mRNAwere normalized to those
of NeoR mRNA to confirm that these phenomena dominantly
occurred by miR-150–mediated AANAT reduction and were
not caused by exogenous AANAT mRNA. Minimal AANAT
mRNA changes were observed among transfected cells (Fig 5,
D and E, bottom). AANAT mRNA levels were relatively higher
in human Prf1 (>1.6-fold), but the AANAT protein expression
was rather downregulated by the miR-150 mimic (Fig 5, E, bot-
tom, lane 2). Taken together, these data suggest that Prf1 is a
conserved functional target of miR-150 in both mouse and hu-
man NK cells.Lentivirus-mediated overexpression of miR-150
shows a significant decrease in Prf1 levels and
diminished NK cell–mediated cytotoxicity
miR-1502/2NK cells were transduced by lentivirus containing
miR-150 precursor (LV-miR150) and cultured in a high concen-
tration of IL-15 (100 ng/mL) for 2 days to test whether miR-150
overexpression and miR-150 deficiency would cause opposite ef-
fects onmouse or humanNK cells. Lentivirus-mediated upregula-
tion of miR-150 markedly repressed Prf1 protein expression
compared with that seen in cells transduced with a control vector
(Fig 6,A), which led to diminishedNK cell cytotoxicity (Fig 6,B).
In this case higher NK cell cytotoxicity was observed at a high
concentration of IL-15 (100 ng/mL; Fig 6, B) compared with a
modest concentration of IL-15 (25 ng/mL; Fig 2, B) at the same
E/T ratio.
Compared with in vitro–differentiated human mature NK
cells, NK92 MI cells expressed a significantly low level of
endogenous miR-150 (Fig 6, C) and thus were selected for
applying lentivirus-mediated overexpression. During lentiviral
transduction, the miR-150 level in NK92 MI cells was increased
in a time-dependent manner (Fig 6, D). Modest upregulation of
miR-150 after 2 days of lentiviral transduction did not change
human Prf1 protein, but robust expression of miR-150 signifi-
cantly inhibited Prf1 production at 4 days after lentivirus 150
transduction (Fig 6, D and E), which contributed to reduced
NK cell cytotoxicity (Fig 6, F). Collectively, these data imply
that overexpression of miR-150 can act as a negative regulator
of NK cell lytic activity by repressing Prf1 in both mouse and
human NK cells.miR-1502/2 NK cells significantly reduce tumor
growth and metastasis in immunocompromised
mice
To investigate the role for miR-150 in immune surveillance
against tumor cells in vivo, activated NK cells were injected intra-
venously, and then B16F10melanomawere transplanted subcuta-
neously into Rag22/2gC2/2 mice, which lack B, T, and NK
cells.21 The adoptive transfer of miR-1502/2 NK cells signifi-
cantly reduced tumor volumes to an average of 71.23 6 20.31
mm3 (mean 6 SD, n 5 5), but WT NK cells less substantially
FIG 3. miR-150 has no significant effects on NK cell receptor profiles (A), degranulation (B), and death
receptor/ligand interactions (C). WT and miR-1502/2 NK cells were cultured in IL-15 for 48 hours, and
then cell surfaces were stained with indicated antibodies. Anti-NKp46 antibody was used to activate
NKp46 receptors on NK cells. Data represent means 6 SDs of 3 independent experiments. FasL, Fas ligand;
TRAIL, TNF-related apoptosis-inducing ligand.
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 1
KIM ET AL 199reduced tumor volumes, with an average of 146.626 109.34mm3
(mean 6 SD, n 5 5) on day 11 after B16F10 implantation
(Fig 7, A).
NK cells also play critical roles in reducing lung metastasis
in various murine cancer models, and Prf1 is highly involved in
the inhibition of tumor metastasis.22 Activated WT and miR-
1502/2 NK cells were injected intravenously and then highly
metastatic murine B16F10 cells were injected into the tail veins
of Rag22/2gC2/2 mice at 2 days after NK cell transplantation
to define the potential role for miR-150 in limiting lung metas-
tasis of melanoma in vivo. The numbers of pulmonary metasta-
tic colonies were quantitated and photographed at 14 days after
B16F10 implantation (Fig 7, B and C). miR-1502/2 NK cells
effectively inhibited lung metastasis of B16F10 melanoma to
an average of 170.71 6 25.23 (mean 6 SD, n 5 7) compared
with WT NK cells, with an average of 65.67 6 21.42 (mean 6
SD, n 5 6; Fig 7, B). Taken together, these results demonstrate
that miR-1502/2 NK cells exhibit augmented NK cellcytotoxicity against tumor growth and lung metastasis of
B16F10 melanoma in immunodeficient mice.DISCUSSION
Prf1 was first isolated and characterized from cytotoxic
lymphocytes in the mid-1980s, and significant progress has
been made in understanding how NK cells use Prf1 to eliminate
target cells. However, our knowledge of how preformed Prf1
mRNA is posttranscriptionally regulated in resting NK cells is
still limited. Recent achievements have highlighted the impor-
tance of miRNA-mediated Prf1 regulation in human NK cells,
and 2 studies have been summarized.23,24 A study from our labo-
ratory demonstrated that miR-27a* targeted the 39 UTRs of Prf1
and GzmB in in vitro–differentiated human NK cells at rest or
after IL-15 activation.20 However, freshly isolated resting human
NK cells expressed very low levels of miR-27a*.25 This suggests
that in vitro–differentiated human NK cells that result from
FIG 4. miR-1502/2 NK cells induce a potent lytic hit at the immunologic synapse. A-C, NK cells were stained
with LysoSensor (Fig 4, A), Prf1 (Fig 4, B), or CD107a (Fig 4, C). D and E, Dynamic interfaces formed between
NK cells and target cells were photographed (Fig 4, D) and illustrated (Fig 4, E). F-H, Percentage of NK cells
remaining at each step (Fig 4, F); kinetics of steps C, D, and E (Fig 4,G); and cytotoxicity (Fig 4, H).MFI, Mean
fluorescence intensity. *P < .05.
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different miRNA expression than freshly isolated primary human
NK cells. Liu et al25 reported that miR-30e repressed Prf1 in hu-
man NK cells on IFN-a stimulation. The miR-30e level wasshown to be inversely associated with Prf1 protein expression
in vitro, but its role in immune surveillance against tumor cells
in vivo remains to be elucidated. Although these studies address
the role of miRNAs in human NK cells, extensive research on
FIG 5. miR-150 directly targets Prf1 in NK cells.A-C, Scheme of reporter vector (Fig 5,A) and sequence align-
ments of miR-150 to target cells (Fig 5, B and C). D and E, 39 UTR AANAT reporter containing mouse GzmB/
Prf1 (Fig 5, D) or human Prf1/GzmB (Fig 5, E) were cotransfected with indicated miRNAs, and then AANAT
proteins and mRNAs were analyzed. Data represent means 6 SDs of 3 independent experiments. 1, 50
nmol/L; 11, 100 nmol/L. pA, Polyadenylation. P < .01.
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 1
KIM ET AL 201miRNA-mediated Prf1 regulation in both mouse and human NK
cells at rest and at various time points after activation has not
been investigated.
Here we report that miR-150 posttranscriptionally regulates
Prf1 in freshly isolated primary mouse and human NK cells at
rest and after IL-15 activation. Unlike exogenous Prf1 gene
transfer to NK cells, which constitutively express Prf1 without
stimuli, an inverse correlation between miR-150 levels and
Prf1 expression during IL-15 activation serves 2 purposes. First,
mature resting or insufficiently activated NK cells contain
substantial amounts of endogenous miR-150, which prevents
spontaneous activation of the newly generated NK cells without
adequate stimuli through repression of pre-existing Prf1 mRNA
translation. Second, reduced miR-150 expression in fully
activated NK cells allows enhanced production of Prf1 from
preformed Prf1 mRNA for prompt and potent immune
responses.
Even though miR-1502/2 NK cells exhibited amplified Prf1
translation at 48 and 72 hours of IL-15 stimulation, resting
miR-1502/2 NK cells still minimally express Prf1 protein simi-
larly to resting WT NK cells (Fig 2, A, top). Xiao et al14 also re-
ported that activated miR-1502/2B cells highly expressed c-Myb
protein, a known target of miR-150, compared withWT B cells at48 and 72 hours of anti-IgM stimulation, but resting miR-1502/2
B cells minimally expressed c-Myb protein. How resting
miR-1502/2 NK cells are minimally cytotoxic still needs to be
clarified, but this phenomenon makes miR-1502/2 NK cells
more attractive for adoptive NK cell therapy because of their
unique ability to maintain minimal cytotoxicity at rest while ex-
hibiting maximal lytic activity on activation.
miR-150 is highly upregulated in mature B, T, and NK cells but
not in their progenitors.12-16 Ectopic expression of miR-150 in
mouse B-cell precursors leads to severe defects in B-cell develop-
ment at the transition from the pro-B-cell to pre-B-cell stage by
targeting c-Myb, but impairment of T-cell development was
less severe.14,26 miR-1502/2 mice have significant reductions in
NK cell development and maturation.12 Here we revealed that
the same number ofmiR-1502/2NKcells showed enhanced cyto-
toxicity compared with that in WT NK cells by augmented Prf1
production, which led to more powerful lytic hits to target cells.
Collectively, this implies that miR-1502/2 mice might compen-
sate for reduced numbers of mature NK cells by alternately
improving NK cell effector function.
miR-150 also plays a critical role as a tumor suppressor by
targeting the proto-oncogene c-Myb and Notch3. miR-150 is
significantly downregulated in patients with severe sepsis,27 a
FIG 6. A, B, E, and F, Lentivirus (LV)–mediated overexpression of miR-150 suppresses Prf1 and cytotoxicity.
After lentiviral transduction, miR-1502/2 NK and NK92 MI cells showed decreased Prf1 protein (Fig 6, A and
E) and NK cell cytotoxicity (Fig 6, B and F), respectively. C and D, Low endogenous miR-150 in NK92 MI cells
(Fig 6, C) was increased after lentiviral transduction (Fig 6, D). Data represent means6 SDs from 3 indepen-
dent experiments. mNK, Mature NK cell. *P < .05 and **P < .01.
FIG 7. miR-1502/2 NK cells exhibit enhanced tumor surveillance in immu-
nocompromised mice. Adoptive transfer of miR-1502/2 NK cells effectively
reduced tumor growth (A) and lungmetastasis of B16F10melanoma (B and
C) compared with that seen in WT NK cells in Rag22/2gC2/2 mice. Data
represent means 6 SDs of 2 independent experiments. *P < .05.
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malignant NK/T-cell lymphomas,30 colorectal cancers,31 and
hepatocellular carcinomas.32 Therefore, miR-150 was highly
expressed in normal mature NK cells but significantly downregu-
lated in NK92 MI cells derived from a patient with non-Hodgkin
lymphoma (Fig 6, C). Lentivirus-mediated overexpression of
miR-150 in NK/T-cell lymphoma cells resulted in increased
expression of tumor suppressors, such as p53 and Bim, and
decreased levels of AKT2, becomingmore susceptible to the anti-
cancer drug etoposide.30 On the contrary, the transcription levels
of the proto-oncogenes c-Myb, c-kit, and Bcl-2 were increased insorted miR-1502/2NK cells,12 which raises the interesting possi-
bility that miR-1502/2 NK cells could be more resistant to anti-
cancer drugs.
These data suggest that the downregulation of miR-150 confers
a growth advantage to malignant cells, as well as premature and
activated lymphocytes, possibly by upregulating c-Myb and Bcl-
2. On activation, miR-150was downregulated inmature B, T, NK,
and invariant NK T cells, potentially releasing mature lympho-
cytes from growth arrest and allowing rapid proliferation to occur
for proper immune responses.
In summary, the downregulation of miR-150 can be a
promising approach to NK cell therapies by enhancing NK
cell cytotoxicity while possibly reducing NK cell apoptosis to
anticancer agents. The ultimate goal of immunotherapy in
many settings would not only include boosting the tumor-
killing ability of immune effector cells but also making the
effector cells more resistant to the anticancer drugs being
concurrently administered to patients.33 Additionally, one study
reported that allergen-specific cytotoxic T cells require
sufficient Prf1 expression to suppress allergic airway inflamma-
tion.34 This implies that NK cells might contribute to Prf1-
mediated allergic responses. Actually, NK cells have been
reported to be involved in allergic diseases.35-37 Patients with
atopic dermatitis showed defects in NK cell cytotoxicity and
IFN-g production.38 Thus therapeutic control of miR-150 in
NK cells potentially opens new avenues for enhanced
miRNA-mediated NK cell immunotherapy against various hu-
man pathologies, including cancer and allergy, providing a bet-
ter clinical outcome.
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d miR-150 posttranscriptionally downregulated Prf1
expression in both mouse and human NK cells at rest
and after IL-15 activation.
d Activated miR-1502/2 NK cells expressed upregulated
Prf1, augmenting cytotoxicity.
d The adoptive transfer of miR-1502/2 NK cells signifi-
cantly reduced tumor growth and metastasis of B16F10
melanoma in immunocompromised mice.REFERENCES
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Mice
WT C57BL/6J, miR-1502/2, and Rag22/2gC2/2 mice were purchased
from Jackson Laboratories and were bred and maintained under specific
pathogen-free conditions. For mouse experiments, sex- and age-matched 8-
to 12-week-old mice were used in accordance with the guidelines of the
KRIBB Institutional Animal Care and Use Committee. The KRIBB Animal
Welfare Assurance number was KRIBB-AEC-11039.
Primary NK cell preparations and cell culture
Primary mouse NK cells were isolated from the spleen by using the mouse
NK Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany),
according to the manufacturer’s protocol. Enriched mouse NK cells (>90%
NK1.11) were cultured in RPMI 1640 (WelGENE, Daegu, Korea) containing
10% FBS (Thermo Scientific Hyclone) and 1% penicillin-streptomycin-
amphotericin B (WelGENE) supplemented with either 25 or 100 ng/mL
recombinant mouse IL-15 (PeproTech, Rocky Hill, NJ), depending on the
purpose of the experiments. Primary human NK cells were obtained from
umbilical cord blood by using ACCUSPIN System-Histopaque-1077
(Sigma-Aldrich, St Louis, Mo) density separation. NK cells were then
enriched by means of negative selection with the MACS NK cell isolation
kit, according to the manufacturer’s instructions (Miltenyi Biotec). Highly
enriched NK cell populations (>93% CD561/CD32 and <5% CD31) were
maintained in IL-15 (30 ng/mL)–supplemented culture medium. Human
CD341 hematopoietic precursors were differentiated in vitro from umbilical
cord blood, as described previously,E1 to obtain in vitro–differentiated human
NK cells. The populations of terminally differentiated mature NK cells were
90% CD561CD32 or greater. The YAC-1 and K562 cells were cultured in
RPMI 1640 (WelGENE) supplemented with 10% FBS (Hyclone) and 1%
penicillin-streptomycin-amphotericin B (WelGENE; referred to as complete
RPMI medium). The human NK cell line NK92 MI was cultured in a-MEM
(Gibco, Carlsbad, Calif) supplemented with 20% heat-inactivated FBS (Hy-
clone) and 2 mmol/L L-glutamine. Human embryonic kidney (HEK) 293FT
cells and B16/F10 cells were maintained in Dulbecco modified Eagle
medium (DMEM) containing 10% FBS and 1% penicillin-streptomycin-
amphotericin B (referred to as complete DMEM medium). Cells were main-
tained under 378C and 5% CO2 conditions.
Lentiviral transduction
For lentiviral transduction, the pMIRNA1-GFP control vector and pMIR-
150 vector encoding precursor-miR-150 were obtained from System
Biosciences (Mountain View, Calif). Lentiviruses were produced by using a
third-generation packaging system (pMDLg/pRRE, pRSV-Rev, and pMD2.G)
in HEK293FT cells, as previously described,E2 with minor modifications. Af-
ter 48 hours of transfection, the lentivirus-containing supernatants were
filtered through a 0.45-mm filter and mixed with PEG-it Virus Precipitation
Solution (System Biosciences) overnight, concentrated by means of centrifu-
gation at 1500g for 30 minutes at 48C, and stored at2708C. Frozen infectious
supernatants were used to infect primary mouse NK cells or human NK92 MI
cells. Transduced cells were replenishedwith half the amount of freshmedium
every 24 hours and allowed to grow for approximately 48 to 96 hours, depend-
ing on the cell types.
Kinetic analysis of effector molecule expression
Primary human and mouse NK cells were freshly incubated in the presence
of IL-15 (30 ng/mL). The cells were harvested at the times indicated (0, 6, 12,
24, and 48 or 72 hours) relative to IL-15 addition. Kinetic analysis of Prf1 and
GzmB expression in NK cells during activation was performed with
immunoblot analyses and cDNA quantification by means of semiquantitative
PCR or real-time quantitative PCR analyses by using the specific primer pairs
shown in Table E1. Band intensities of Prf1 and GzmB proteins and cDNAs
were normalized with those of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) or actin and plotted as a relative amount at time zero (0 hours, value
1). The quantitative data are expressed as the mean value of independent mea-
surements from 2 separate experiments (mean 6 SEM).In vivo tumor challenge experiments
Purified mouse NK cells (63 105) were cultured in a high concentration of
mouse IL-15 (100 ng/mL) for 24 hours and then injected intravenously into
Rag22/2gC2/2 recipient mice (n 5 5). After 2 hours, B16F10 cells (4 3
105) were injected subcutaneously into the shaved lateral flanks of those
mice. The size of primary tumors was monitored on day 11 with a caliper.
Tumor volume was calculated with the following formula:
V5 ðA3B3CÞ=2;
where V is defined as volume (in cubic millimeters), A if defined as length (in
millimeters), B is defined as width (in millimeters), and C is defined as height
(in millimeters). A well-established experimental lung metastasis model was
used with modifications to validate NK cell–mediated control of lungmetasta-
sis.E3 WT and miR-1502/2 NK cells (2 3 105 cells) were stimulated with
high-dose IL-15 (100 ng/mL) for 12 hours and injected intravenously into
Rag22/2gC2/2 mice. B16F10 melanoma cells (1 3 105 cells) were injected
into the tail veins of Rag22/2gC2/2mice 2 days after NK cell injection. Lungs
were harvested and examined visually for melanoma clones after 14 days.
Numbers of pulmonary metastatic colonies were quantitated by means of
counting.
Semiquantitative PCR and real-time PCR
Total RNAs were extracted from cells by using an RNA-spin kit (iNtRON
Biotechnology, Gyeonggi-do, South Korea), and 1 mg of RNA was reverse
transcribed into cDNA by using a ReverTra Ace a–First Strand cDNA
Synthesis Kit (Toyobo, Osaka, Japan), according to the manufacturer’s
protocol. For semiquantitative PCR, 27 cycles of PCR amplification were
performed as follows: 958C for 30 seconds, 558C for 30 seconds, and 728C for
30 seconds, followed by an extension step at 728C for 5 minutes. The PCR
products were visualized with agarose gel electrophoresis and ethidium
bromide. Real-time PCR was performed with a Dice TP800 Thermal Cycler
(Takara Bio, Shiga, Japan) and the SYBR Premix Ex Tag (Takara Bio). The
data were normalized to the amount of GAPDH transcript. The primer
sequences are shown in Table E1. For real-time PCR of mature miR-150, total
RNAswere extracted with an RNeasymini kit (Qiagen, Hilden, Germany) and
reverse transcribed with the TaqMan MicroRNA Reverse Transcription Kit.
The level of miR-150 was examined by using the TaqMan MicroRNA Assays
specific for miR-150 (Applied Biosystems, Foster City, Calif), and U6 small
nuclear RNA was used to normalize the relative abundance of miR-150,
according to the manufacturer’s instructions.
Western blotting
Cells were washed with PBS and lysed in RIPA buffer (Thermo Fisher
Scientific,Waltham,Mass) supplementedwith a protease inhibitor cocktail set
III (Calbiochem, San Diego, Calif). After rapid sonication, the cell lysates
were electrophoresed on 10% Tris-glycine SDS-polyacrylamide gels and
transferred to a polyvinylidene difluoride membrane (Millipore, Temecula,
Calif). The membranes were incubated with anti-mouse Prf1 (Cell Signaling,
Danvers, Mass), anti-GzmB (Abcam, Cambridge, United Kingdom), anti-
human Prf1 (Abcam), anti-AANAT (gift from Dr Klein), and anti–b-actin
(Sigma-Aldrich), followed by anti-rabbit or anti-mouse IgG (Jackson
ImmunoResearch, West Grove, Pa) conjugated to horseradish peroxidase.
Immunoreactive bands were visualized with SuperSignal West Pico Chemi-
luminescent Substrate (Pierce, Rockford, Ill) or Immobilon Western Chemi-
luminescent HRP Substrate (Millipore) and photographed with EZ-capture
(ATTO, Amherst, NY).
NK cell cytotoxicity assays
NK cell–mediated cytotoxicity was examined with a standard 4-hour 51Cr-
release assay or calcein-AM cytotoxicity assay. In brief, YAC-1 cells were
incubated with 1.5 mCi of 51Cr, and K562 cells were incubated with 15
mmol/L calcein-AM for 1 hour. The 51Cr-labeled YAC-1 cells or calcein-
AM–labeled K562 cells (1 3 104 cells per well) were placed into a 96-well
round-bottom plate in triplicate and cocultured either with mouse or human
NK cells at E/T ratios ranging from 20:1 to 1.25:1 for 4 hours. The 51Cr release
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g-counter, and the calcein release from lysed K562 cells by human NK cells
was measured with a spectrofluorometer (excitation filter, 485 nm; emission
filter, 535 nm). The percentage of specific lysis was calculated according to
the following formula:
ðExperimental release2Spontaneous releaseÞ=
ðMaximum release2Spontaneous releaseÞ3100:
Spontaneous release refers to 51Cr or calcein released from target cells in
complete medium alone, whereas maximum release refers to 51Cr or calcein
released from target cells in complete medium containing 1% Triton X-100.
To investigate the effect of activating receptors on NK cell cytotoxicity be-
tween WT and miR-1502/2 NK cells, we pretreated IL-15–activated primary
mouse NK cells with 5 mg/mL anti-NKp46 antibody (BioLegend, San Diego,
Calif) for 2 hours before the cytotoxicity assay. Next, we stained NK cells
alone with phycoerythrin-conjugated anti-mouse CD107a (BD Biosciences,
San Jose, Calif) or NK cells cocultured with YAC-1 target cells (1 3 104)
for 2 hours at 378C and performed by using standard flow cytometry.
Flow cytometry
Purified mouse NK cells were cultured in complete RPMI medium
supplemented with IL-15 (25 ng/mL) for 48 hours. Activated NK cells (1 3
105) were resuspended in PBS containing 1% FBS and stained for 20 minutes
at 48C with 1 or 2 of the following antibodies: phycoerythrin-conjugated anti-
mouse-NKG2D, CD122, CD132, CD95, CXCR5, CCR6, or Ly49C/I or fluo-
rescein isothiocyanate–conjugated anti-mouse-NKp46, Ly49D, Ly49A, or
Ly49G2 (from BD Biosciences, BioLegend, or eBioscience). For the degran-
ulation assay, IL-15–activated NK cells (1 3 105) were stained with
phycoerythrin-conjugated anti-mouse CD107a (BD Biosciences) and either
used alone or cocultured with YAC-1 target cells (1 3 104) for 1 hour at
378C in the dark, and unstained NK cells alone served as a negative control.
Golgi-stop (BD Biosciences) was added at a final concentration of 6 mg/mL
and incubated for an additional 4 hours at 378C. For the detection of intracy-
toplasmic Prf1 in NK cells, mixed cell populations were stained with
allophycocyanin-conjugated anti-mouse NK1.1 (BD Biosciences) for 30
minutes at 48C, fixated, and then permeabilized for 20 minutes at 48C. After
staining with anti-mouse Prf1 antibody, flow cytometry was performed on a
BD FACSCanto II device, and data were analyzed with FlowJo software
(Tree Star).
Live cell imaging
NK cells (1 3 107/mL) were loaded with 1 mg/mL of LysoSensor Green
DND-153 (Invitrogen, Carlsbad, Calif) by incubating at 378C for 30 minutes.
YAC-1 cells (5 3 106/mL) were labeled with 10 mg/mL CellTrace Far Red
DDAO-SE (Invitrogen) by incubating at 378C for 15 minutes. The
LysoSensor-labeledNK cells (approximately 2-53 105) in completeRPMIme-
dium containing 10 mg/mL PI were seeded onto an anti-CD44–coated glass
cover slip loaded in aChamlidemagnetic chamber (LiveCell Instrument, Seoul,
Korea). The NK cell–seeded chamber was mounted on a microscope stage
equipped with a Chamlide TC incubator system (Live Cell Instrument), main-
tained at 378C and 5% CO2, and incubated for 30 minutes. Then DDAO-
labeled YAC-1 target cells were gently added into the magnetic chambercontaining NK cells, and time-lapse imaging was performed in 3-minute inter-
vals for 2 hours. A modified Zeiss Axio Observer Z1 epi-fluorescence micro-
scope (Zeiss, Oberkochen, Germany) with a 40X (Plan-Neofluar, NA 5 1.30)
objective lens and a Roper Scientific CoolSnap HQCCD camera (Roper Scien-
tific, Ottobrunn, Germany) were used for imaging. Differential Interference
Contrast (DIC) and green (LysoSensor, EX BP 470/40, BS 495, EMBP 525/
50), red (PI, EX BP 550/25, BS 570, EMBP 605/70), and far red (DDAO, EX
BP 620/60, BS 660, EMBP 770/75) fluorescence images were acquired in rapid
succession at each time interval. For LysoSensor imaging, 3 optical section
images over 1.5-mm distances in the z-direction were acquired and integrated.
Image processing and analysis were performed with ImageJ software (National
Institutes of Health) and Metamorph (Molecular Devices, Sunnyvale, Calif).
Plasmid constructions
Total RNAs were extracted from mouse primary NK cells or human NK92
cells and reverse transcribed with oligo(dT) to construct chimeric AANAT
reporter plasmids (Toyobo). The cDNAs for human andmouse Prf1 andGzmB
39 UTRs were amplified with specific primers (Table E2), and the amplifica-
tion of cDNAwas confirmed by means of sequencing. The PCR products of
human Prf1, human GzmB, and mouse Prf1 were digested with EcoRI and
XbaI, and the PCR product of mouse GzmB was cleaved with XhoI and
then cloned into the EcoRI/XbaI sites and the blunt/XhoI site of the reporter
pcAANAT,E4 respectively.
Transfection
For AANAT reporter assays, HEK293FT cells were seeded at 43 105 cells
per well in 12-well plates without antibiotics and grown overnight. After the
cells reached 85% to 90% confluence, they were cotransfected with 1 mg of
AANAT plasmids containing 39 UTR of Prf1 or GzmB combined with either
miR-150 mimics, miR-150 mutants, or a nontargeting control (Dharmacon,
Lafayette, Colo) at concentrations of approximately 50 to 100 nmol/L by using
Lipofectamine 2000 and Plus (Invitrogen), per the manufacturer’s protocol.
After 16 hours of transfection, transfection medium was replaced with com-
plete DMEM medium, and cells were grown for a further 48 hours.
Statistical analyses
Comparisons between samples were analyzed for statistical significance by
using the Student t test with Microsoft Excel software. A P value of less than
.05 was considered significant.
TABLE E1. Primer sequences used for real-time PCR
Gene name Direction Sequence
Human Prf1 Forward 59-GCTGGACGTGACTCCTAAGC-39
Reverse 59-GATGAAGTGGGTGCCGTAGT-39
Human GzmB Forward 59-GTAAGGGGGAAACAACAGCA-39
Reverse 59-CCCCAAGGTGACATTTATGG-39
Mouse Prf1 Forward 59-TTCGGGAACCAAGCTACACCA-39
Reverse 59-CAGGCTGTAGTCCACCAGACCA-39
Mouse GzmB Forward 59-AAGAACTGGGTGTTGACTGCTG-39
Reverse 59-CACGTGTATATTCATCATAGCATGG-39
NeoR Forward 59-ATGACTGGGCACA-ACAGACA-39
Reverse 59-AGTGACAACGTCGAGCACAG-39
AANAT Forward 59-CATCTGCCTCTTGGGACCT-39
Reverse 59-AGCTCTGGACACAGGGTGAG-39
Mouse GAPDH Forward 59-TCAACAGCAACTCCCACTCTTCCA-39
Reverse 59-ACCCTGTTGCTGTAGCCGTA-TTCA-39
Human GAPDH Forward 59-GCCATCAATGACCCCTTCATT-39
Reverse 59-GCTCCTGGAAGATGGTGGTGATGG-39
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TABLE E2. Oligonucleotides used to generate AANAT reporter plasmids containing the 39 UTR of Prf1 or GzmB in mice or human
subjects
Inserts Direction Sequence
Mouse Prf1 39 UTR Forward 59-AAGAATTCTAACATAATAACA-39
Reverse 59-AATCTAGAGGGAGAAGGGATTTAAAG -39
Mouse GzmB 39 UTR Forward 59-AAGAATTCTACAGAAGCAACATGGA-39
Reverse 59-AACTCGAGATCAGGTTATACCTTGA -39
Human Prf1 39 UTR Forward 59-AAGAATTCTGAGAACAGTGAGCTTGG-39
Reverse 59-AATCTAGACACCATAACATCATATT -39
Human GzmB 39 UTR Forward 59-AAGAATTCCTACAGGA-AGCAAACTA -39
Reverse 59-AATCTAGACCACTCAGCTAAGAGGT-39
Flanking sequences for cloning purposes are underlined.
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